Importantly, endocannabinoid hydrolysis inhibitors tend to have a safer pharmacological profile as compared to direct CB1 agonists, as they seem less prone to induce psychosis, motor impairment, and addiction, which can be attributed to the on-demand functioning of endocannabinoids (Asth et al., 2019). This evidence concerns the gene CNR1 and psychotic disorder.